Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced its financial results for the third quarter of 2024, highlighting a robust 19.5% year-on-year (YOY) increase in net sales, which reached USD 4.209 billion.
The company’s business units reported significant growth, with MedSurg contributing USD 1.479 billion, marking a 10.4% YOY increase, and Cardiology generating USD 2.731 billion, reflecting a substantial 25.1% YOY increase. Geographically, the U.S. market saw a surge of 23.5%, attributed to new product launches and a rise in market demand. The Europe, Middle East, and Africa (EMEA) region experienced a 14.3% growth, primarily due to new product approvals and market expansion. The Asia Pacific (APAC), Latin America and Canada (LACA), and Emerging Markets also demonstrated strong growth, with increases of 12.3%, 15.1%, and 16.8% respectively.
Looking ahead, Boston Scientific anticipates a net sales growth of approximately 16.5% on a reported basis and 15% on an organic basis for the full year of 2024, indicating continued momentum across its global operations.- Flcube.com
